Projects In Knowledge Presents

[Learning Objectives] [Accreditation Information]
[Disclosure Information] [Instructions for obtaining CME credit]

[CME Posttest] [Symposium Program]
[Symposia Main Page]

Learning Objectives

This activity is designed for gastroenterologists with a fundamental clinical understanding of assessment, diagnosis, treatment, and ongoing management of patients with hepatitis C.

After participating in this activity, the physician should be able to:

• Formulate state-of-the-art treatment strategies for patients with chronic hepatitis C virus (HCV) infection and recognize how thinking regarding these patients has changed over the past year
• Compare the safety and efficacy of combination therapy (interferon/ribavirin) to interferon monotherapy in HCV-infected patients who have experienced a relapse after response to interferon alone
• Evaluate the possible role of combination therapy in the following HCV-infected patient groups: treatment-naive patients, patients who fail to respond to interferon monotherapy, and posttransplant patients
• Describe the possible role of interferon therapy to prevent the development of cirrhosis and hepatocellular carcinoma in HCV-infected patients
• Adjust doses, dosing frequencies, and duration of treatment to optimize a patient's sustained response to control chronic HCV infection
• Describe the scientific basis for new developments in antiviral agents in the management of hepatitis C

Accreditation Information

Projects In Knowledge is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education (CME) for physicians.

Projects In Knowledge designates this educational activity for up to 1.5 hours in category 1 credit toward the AMA Physician's Recognition Award. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Release date: July 7, 1998. This material has been planned, produced, and approved as a continuing medical education (CME) activity. This enduring activity will be reviewed within 3 years of its release date and rereleased, or its designation for CME credit will become invalid.

Estimated time for completion of this activity: 1.5 hours. This activity is designated for 1.5 hours of CME credit with a passing score of 70% or higher on the posttest.

This designation is valid through July 7, 2001.

Disclosure Information

The Disclosure Policy of Projects In Knowledge requires that faculty participating in a CME activity disclose to the audience any significant relationship they may have with a pharmaceutical or medical equipment company product or service that may be mentioned as part of their presentation, as well as any relationship with the commercial supporter of this activity.

This independent CME activity is supported by an unrestricted educational grant from Schering Oncology/Biotech.

• Willis C. Maddrey, MD, is a consultant for Amgen, Glaxo Wellcome, and Schering Laboratories.
• Eugene R. Schiff, MD, has received grants/research support from Glaxo Wellcome, Schering Laboratories, and SmithKline Beecham; has been a consultant for Amgen, Glaxo Wellcome, and Schering Laboratories; and has been a speaker for Astra Merck, Glaxo Wellcome, and Schering Laboratories.
• Gary L. Davis, MD, has received grants/research support from Schering Laboratories, and is a consultant for Gilead Sciences and ViroPharma.
• Adrian M. Di Bisceglie, MD, has received grants/research support from Cellor, Gilead Sciences, Roche Pharmaceuticals, and Schering Laboratories; is a consultant for Cellor and SciClone; and is on the speakers bureau of Schering Laboratories.
• Robert G. Gish, MD, has received grants/research support from Abbott Laboratories, Amgen, Chiron Therapeutics, and Schering Laboratories; and is a consultant for and a member of the speakers bureaus of Amgen, Chiron Therapeutics, Roche Pharmaceuticals, and Schering Laboratories.

This CME activity is planned and produced in accordance with the ACCME Essentials and Standards for Commercial Support.

The opinions expressed during this activity are those of the faculty and do not necessarily reflect those of the sponsor or the commercial supporter.

This activity may include a discussion of therapies that are unapproved for use or investigational, ongoing research, or preliminary data.

Instructions for obtaining CME credit

Attend the online Beyond Monotherapy: Next Generation Therapies for Chronic Hepatitis C symposium by listening and viewing each of the presentations.

Return and complete the posttest and evaluation summary for the symposium. Physicians interested in earning this credit should answer all questions, then click the <SUBMIT> button that follows the evaluation or click the <PRINT> button and fax to (201) 617-7333 or mail to:

Projects In Knowledge
One Harmon Plaza
Secaucus, NJ 07094

Begin the CME Posttest